Scholar Rock Holding (STU:2QK) Interest Expense : €0.00 Mil (TTM As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Scholar Rock Holding Interest Expense?

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Scholar Rock Holding's interest expense for the three months ended in Sep. 2024 was € 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Sep. 2024 was €0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Scholar Rock Holding's Operating Income for the three months ended in Sep. 2024 was € -58.37 Mil. Scholar Rock Holding's Interest Expense for the three months ended in Sep. 2024 was € 0.00 Mil. GuruFocus does not calculate Scholar Rock Holding's interest coverage with the available data. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scholar Rock Holding Interest Expense Historical Data

The historical data trend for Scholar Rock Holding's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Scholar Rock Holding Interest Expense Chart

Scholar Rock Holding Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Interest Expense

Get a 7-Day Free Trial

Scholar Rock Holding Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Interest Expense	Get a 7-Day Free Trial															-	-	-	-	-

Scholar Rock Holding Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00 Mil.

Scholar Rock Holding (STU:2QK) Interest Expense Explanation

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Scholar Rock Holding's Interest Expense for the three months ended in Sep. 2024 was €0.00 Mil. Its Operating Income for the three months ended in Sep. 2024 was €-58.37 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Sep. 2024 was €54.57 Mil.

Scholar Rock Holding's Interest Coverage for the quarter that ended in Sep. 2024 is calculated as

GuruFocus does not calculate Scholar Rock Holding's interest coverage with the available data.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Ben Graham prefers companies' interest coverage to be at least 5. Scholar Rock Holding Corp has enough cash to cover all of its debt. Its financial situation is stable.

Scholar Rock Holding Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Scholar Rock Holding Corp (STU:2QK) » Definitions » Interest Expense

Comparable Companies

Traded in Other Exchanges

SRRK:USA

Address

301 Binney Street, 3rd Floor, Cambridge, MA, USA, 02142

Website

https://www.scholarrock.com

Scholar Rock Holding Corp is a biopharmaceutical company. It is engaged in the discovery and development of innovative medicines for the treatment of serious diseases including neuromuscular disorders, cancer, fibrosis, and anemia. Geographically, the company operates in the United States. The company's product candidate is Apitegroma which is a selective, fully human, monoclonal antibody, with a mechanism of action that results in inhibition of the activation of the growth factor, myostatin, in skeletal muscle. Its other product comprises SRK-181, an inhibitor of the activation of latent transforming growth factor beta-1 ("TGF?1"), for the treatment of cancers that are resistant to anti-PD-(L)1 antibody therapies.

Scholar Rock Holding Headlines

No Headlines